Abstract
Introduction: The importance of genetically modified microorganisms, including probiotics, now widely have considered as attractive vehicles for mucosal delivery of therapeutic molecules. Previous studies have indicated that mucosal administration of these molecules can effectively trigger humoral along with cellular immune responses. Therefore, development of induction of mucosal immune responses, utilizing of recombinant probiotics-based vaccines, as live delivery vectors with no side effects in humans, may contribute to effectiveness of control strategies against infection agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have